期刊文献+

新型抗血小板靶标磷酸肌醇3-激酶β的研究进展

下载PDF
导出
摘要 当血管壁受损时,人体会启动止血途径来保护损伤的血管,但是抗凝血因子超出了正常调控范围,参与凝血的物质就会积聚于血管壁,导致病理性血栓形成。抗血小板药是治疗血栓的一类重要的药物,
出处 《重庆医学》 CAS 北大核心 2017年第28期4000-4003,共4页 Chongqing medicine
基金 重庆市科委基础与前沿基金资助项目(cstc2014jcyjA10125) 重庆市高等教育教学改革研究重点基金资助项目(142083) 重庆医药高等专科学校科研计划基金资助项目(ygz2015107)
  • 相关文献

参考文献1

二级参考文献36

  • 1Engleman, J. A.; Luo, J.; Cantley, L. C. Nat. Rev. Genet. 2006, 7, 60.
  • 2(a) Wong, K.-K.; Engelman, J. A.; Cantley, L. C. Curr. Opin. Genetics Dev. 2010, 20, 87.
  • 3Cantley, L. C. Science 2002, 296, 1655.
  • 4Bartholomeusz, C.; Gonzalez-Angulo, A. M. Expert. Opin. Ther. Targets 2012, 16, 121.
  • 5Novartis’ BYL719, claimed to be the first oral drug that strongly and selectively targets the PI3K-a isoform, has an improved safety profile compared to non-selective PI3K inhibitors.
  • 6Jackson, S. P.; Schoenwaelder, S. M.; Goncalves, 1.; Nesbitt, W. S.; Yap, C. Y.; Wright, C. E.; Kenche, V.; Anderson, K. E.; Dopheide, S. M.; Yuan, Y.; Sturgeon, S. A.; Prabaharan, H.; Thompson, P. E.; Smith, G. D.; Shepherd, P. R.; Daniele, N.; Kulkami, S.; Abbott, B.; Saylik, D.; Jones, C.; Lu, L.; Giuliano, S.; Hughan, S. C.; Angus, J.A.; Robertson, A. D.; Salem, H. H. Nature Medicine 2005, 11, 507.
  • 7(a) AstraZeneca was developing AZD-6482 as an intravenous platelet aggregation inhibitor for the potential treatment of thrombosis. A phase I trial was completed in May 2008; however, by July 2010, the program had been discontinued. The compound is described in W02009093972.
  • 8Nylander, S.; Kull, B.; Bjorkman, J. A.; Ulv-inge, J. C.; Oakes, N.; Emanuelsson, B. M.; Andersson, M.; Skarby, T.; Inghardt, T.; Fjellstrom, O.; Gustafsson, D. J. Thromb. Haemost.2012, 10, 2127.
  • 9Gross, C.; Bassell, G. J. Mol. Med. 2012, 18, 336.
  • 10(a) Wee, S.; Wiederschain, D.; Maira, S.-M.; Loo, A.; Miller, C.; DeBeaumont, R.; Stegmeier, F.; Yao, Y. M.; Lengauer, C. Proc. Natl. Acad. Sci. U. S. A. 2008, 105, 13057.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部